{"id":4018,"date":"2012-04-11T13:37:00","date_gmt":"2012-04-11T13:37:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=4018"},"modified":"2021-07-09T11:26:09","modified_gmt":"2021-07-09T11:26:09","slug":"combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/","title":{"rendered":"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ozeki+K&amp;cauthor_id=23341799\">Keiji Ozeki<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23341799\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Tanida+S&amp;cauthor_id=23341799\">Satoshi Tanida<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Mizoshita+T&amp;cauthor_id=23341799\">Tsutomu Mizoshita<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Tsukamoto+H&amp;cauthor_id=23341799\">Hironobu Tsukamoto<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ebi+M&amp;cauthor_id=23341799\">Masahide Ebi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Mori+Y&amp;cauthor_id=23341799\">Yoshinori Mori<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kataoka+H&amp;cauthor_id=23341799\">Hiromi Kataoka<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Kamiya+T&amp;cauthor_id=23341799\">Takeshi Kamiya<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Joh+T&amp;cauthor_id=23341799\">Takashi Joh<\/a>, Case Rep Gastroenterol. 2012 Sep;6(3):765-71.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p>Adalimumab (ADA) is applied to induce remission in patients with Crohn&rsquo;s disease (CD) na\u00efve to chimeric anti-tumor necrosis factor-\u03b1 (anti-TNF-\u03b1), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granulocyte and monocyte apheresis (GMA) depletes elevated\/activated myeloid lineage leucocytes as sources of inflammatory cytokines and has been used to treat patients with CD. This study was to investigate the efficacy of intensive GMA in combination with ADA as remission induction therapy in cases of CD refractory to medications including anti-TNF-\u03b1 therapies. Between December 2010 and February 2012, 5 consecutive cases with refractory CD were treated with intensive GMA (2 sessions per week) plus ADA to induce remission. CD activity index (CDAI), C-reactive protein (CRP), and endoscopic findings based on the simple endoscopic score for CD (SES-CD) at baseline and 10 weeks post 5 ADA injections were applied to determine treatment efficacy outcomes. At week 10 post ADA treatment, clinical remission together with normal CRP levels were achieved in all 5 cases, while SES-CD scores reflected marked improvement in 3 cases and partial improvement in 2 cases who had extensive deep longitudinal CD lesions. The CDAI and CRP values at baseline were 324 \u00b1 118 and 4.9 \u00b1 3.3 mg\/dl, respectively. The corresponding values after treatment were 100 \u00b1 28 (p = 0.024) and 0.2 \u00b1 0.2 mg\/dl (p = 0.038). In these 5 cases with medication-refractory CD, combination therapy with intensive GMA followed by 5 ADA shots appeared to be an effective and safe intervention for inducing clinical remission.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3551391\/pdf\/crg-0006-0765.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3551391\/pdf\/crg-0006-0765.pdf<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23341799\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/23341799\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Keiji Ozeki&nbsp;1,&nbsp;Satoshi Tanida,&nbsp;Tsutomu Mizoshita,&nbsp;Hironobu Tsukamoto,&nbsp;Masahide Ebi,&nbsp;Yoshinori Mori,&nbsp;Hiromi Kataoka,&nbsp;Takeshi Kamiya,&nbsp;Takashi Joh, Case Rep Gastroenterol. 2012 Sep;6(3):765-71. Adalimumab (ADA) is applied to induce remission in patients with Crohn&rsquo;s disease (CD) na\u00efve to chimeric anti-tumor necrosis factor-\u03b1 (anti-TNF-\u03b1), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granulocyte and monocyte apheresis (GMA) depletes elevated\/activated myeloid [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[251,245,156,252,87],"class_list":["post-4018","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-adalimumab-refractory-patients","scientific_tags-cdai","scientific_tags-safety","scientific_tags-ses-cd","scientific_tags-simple-endoscopic-score"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Keiji Ozeki&nbsp;1,&nbsp;Satoshi Tanida,&nbsp;Tsutomu Mizoshita,&nbsp;Hironobu Tsukamoto,&nbsp;Masahide Ebi,&nbsp;Yoshinori Mori,&nbsp;Hiromi Kataoka,&nbsp;Takeshi Kamiya,&nbsp;Takashi Joh, Case Rep Gastroenterol. 2012 Sep;6(3):765-71. Adalimumab (ADA) is applied to induce remission in patients with Crohn&rsquo;s disease (CD) na\u00efve to chimeric anti-tumor necrosis factor-\u03b1 (anti-TNF-\u03b1), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granulocyte and monocyte apheresis (GMA) depletes elevated\/activated myeloid [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:26:09+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/\",\"name\":\"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2012-04-11T13:37:00+00:00\",\"dateModified\":\"2021-07-09T11:26:09+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte","og_description":"Keiji Ozeki&nbsp;1,&nbsp;Satoshi Tanida,&nbsp;Tsutomu Mizoshita,&nbsp;Hironobu Tsukamoto,&nbsp;Masahide Ebi,&nbsp;Yoshinori Mori,&nbsp;Hiromi Kataoka,&nbsp;Takeshi Kamiya,&nbsp;Takashi Joh, Case Rep Gastroenterol. 2012 Sep;6(3):765-71. Adalimumab (ADA) is applied to induce remission in patients with Crohn&rsquo;s disease (CD) na\u00efve to chimeric anti-tumor necrosis factor-\u03b1 (anti-TNF-\u03b1), infliximab or patients with loss of response to scheduled maintenance infliximab. Adsorptive granulocyte and monocyte apheresis (GMA) depletes elevated\/activated myeloid [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:26:09+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/","name":"Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn\u2019s Disease - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2012-04-11T13:37:00+00:00","dateModified":"2021-07-09T11:26:09+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/combination-therapy-with-intensive-granulocyte-and-monocyte-adsorptive-apheresis-plus-adalimumab-therapeutic-outcomes-in-5-cases-with-refractory-crohns-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/4018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=4018"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=4018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}